Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | The key challenge in kidney cancer

Elizabeth Plimack • 3 Jun 2019
ASCO 2019
Kidney Cancer Cabozantinib Telaglenastat

Elizabeth Plimack, MD, MS, of the Fox Chase Cancer Center, Philadelphia, PA, gives insight as to the current key challenge in treating kidney cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Elizabeth Plimack

3:54
Guadecitabine + atezolizumab in mUC who have progressed after initial checkpoint inhibitor therapy
Elizabeth Plimack • 7 Apr 2021
1:41
Molecular profiling of exceptional responders to cancer therapy
Elizabeth Plimack • 7 Apr 2021
0:57
Areas of unmet need for patients with advanced UC
Elizabeth Plimack • 7 Apr 2021
2:22
JAVELIN Bladder 100: practice-changing data
Elizabeth Plimack • 1 Jun 2020

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:52
LITESPARK-004: ESA use in VHL disease-associated RCC
Benjamin Maughan • 26 Jan 2024
3:04
Evaluating the role of radiotherapy in primary and metastatic RCC
Sophia Kamran • 26 Jan 2024
2:14
Managing renal cell carcinoma after progressing on checkpoint inhibitors
David Braun • 14 Feb 2024
The content of VJOncology is intended for healthcare professionals